We report the case of a 7-year-old patient of short stature who had normal GH secretion, but a very low serum IGF-I level. On admittance, his height and weight were 102.2 cm (-3.8S.D.) and 15.7 kg (-1.8S.D)., respectively.
PATIENTS
of very short stature, with normal GH secretion but a low serum IGF-I level, are rare. In some cases, the short stature results from a mutation in the GH-1 gene or from abnormalities in the GH receptor [1] [2] [3] [4] . We report here a patient of short stature who had normal GH secretion, but a very low serum IGF-I level. His height velocity was noticeably improved by GH treatment. Short stature was noticed at the age of 1 year and gradually became more prominent. On admittance, his height was 102.2 cm (-3.8SD), and his weight was 15.7 kg (-1.8SD).
The upper left eyelid was ptotic.
Further physical examinations showed no abnormalities.
A complete blood count, routine blood chemical tests and serologic tests were all normal. The serum levels of TSH, freeT4, freeT3, LH, FSH and testosterone were also normal. The serum IGF-I level was very low at 29 ng/ml.
His bone age was 2 years and 8 months at the chronological age of 7 years.
Brain CT scan and MRI revealed no abnormalities.
As shown in Table 1 , the serum GH responses to the administration of insulin, L-dopa and glucagon were all normal.
The mean serum GH level during sleep was 18.8 ng/ml.
The change in the serum IGF-I level that occurred in response to GH administration is shown in Figure 1 . The serum IG-F-I level increased to about 120 ng/ml as a result of GH administration.
In view of this response, GH therapy (0.5 U/kg/week) was started at the age of 7 years, and, as a result, his height velocity improved to 9.5 cm/year (Fig. 2) . The serum IGF-I level and his bone age also improved with the therapy. When he was 9 years and five months old, GH treatment was discontinued for 3 months, because his family were moving to another house. During that period, he remained well, but his height did not increase at all. After the resumption of GH treatment, his height began increasing again. No adverse effects of GH treatment have been observed in this patient. GH-1 Gene Analysis: Genomic DNA was isolated from the patient's lymphocytes.
GH-1 gene analysis was performed as described elsewhere [2] . No mutation was detected in the GH-1 gene of this patient.
Discussion
This patient has normal GH responses to pharmacological stimuli as well as normal spontaneous GH secretion.
In addition, the short stature was extreme, and his bone age was also greatly retarded. These findings indicate that he has no GH neurosecretory dysfunction [5] . The laboratory data and the effect of GH administration on this patient suggest that his endogenous GH is biologically inactive and that he might have a mutation in the GH-1 gene.
Mutations in the GH-1 gene have been reported in some patients of short stature with normal GH secretion but a low serum IGF-I level [1, 2] . We analyzed the GH-1 gene of this patient and found no mutation in it. Measurement of the biological activity of GH in this patient is now in progress. Table 1 . Endocrinological data of the patient Fig. 1 . GH (0.1 U/kg) was subcutaneously administered on 3 consecutive days (T ); the serum IGF-I level was examined prior to administration and on the 3rd, 4th and 5th days. 
